Arbutus Biopharma (ABUS) Return on Sales (2013 - 2026)

Arbutus Biopharma has disclosed Return on Sales across 14 years of filings, most recently posting 0.01% for Q1 2026.

• Return on Sales for Q1 2026 came in at 0.01%, up 15.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.01% (up 13.0% YoY), and the FY2025 annual result was 0.02%, up 9.0% from the prior year.
• Return on Sales came in at 0.01% for Q1 2026 at Arbutus Biopharma, up from 0.04% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.01% in Q1 2026 to a low of 0.15% in Q3 2024.
• The 5-year median for Return on Sales is 0.04% (2025), against an average of 0.06%.
• Across the five-year window, Return on Sales declined 10 bps in 2024 and grew 15 bps in 2026, its largest moves.
• Arbutus Biopharma's Return on Sales stood at 0.04% in 2022, then plunged by 156 bps to 0.09% in 2023, then climbed by 12 bps to 0.08% in 2024, then jumped by 47 bps to 0.04% in 2025, then jumped by 122 bps to 0.01% in 2026.
• The last three Return on Sales figures came in at 0.01% (Q1 2026), 0.04% (Q4 2025), and 0.15% (Q3 2025), per Business Quant data.